Financhill
Back

Ascendis Pharma AS Quote, Financials, Valuation and Earnings

Ascendis Pharma AS Price Quote

$134.57
+3.72 (+2.84%)
(Updated: November 26, 2024 at 5:55 PM ET)

Ascendis Pharma AS Key Stats

Sell
30
Ascendis Pharma AS (ASND) is a Sell

Day range:
$129.42 - $133.10
52-week range:
$90.13 - $161.00
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
21.05
P/B ratio:
0%

Volume:
475.7K
Avg. volume:
436K
1-year change:
41.86%
Market cap:
$7.8B
Revenue:
$288.8M
EPS:
$-8.11

How Much Does Ascendis Pharma AS Make?

Is Ascendis Pharma AS Growing As A Company?

  • What Is Ascendis Pharma AS's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.22%
  • What Is Ascendis Pharma AS's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Ascendis Pharma AS Stock Price Performance

What Is Ascendis Pharma AS 52-Week High & Low?

Ascendis Pharma AS Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Ascendis Pharma AS?

  • How Much Debt Does Ascendis Pharma AS Have?
    Total long term debt quarterly is $880.9M
  • How Much Cash Does Ascendis Pharma AS Have?
    Cash and short term investments quarterly total is $698.6M
  • What Is Ascendis Pharma AS’s Book Value Per Share?
    Book value per share is -1.82

Is Ascendis Pharma AS Cash Flow Positive?

Data Unavailable

Ascendis Pharma AS Return On Invested Capital

  • Is Management Doing A Good Job?
    ASND return on invested capital is -89.94%
  • What Is Ascendis Pharma AS Return On Assets?
    ROA measures how assets are converting to revenues and is -48.84%
  • What Is ASND Return On Equity?
    ROE is a measure of profitability and is 0%

Ascendis Pharma AS Earnings Date & Stock Price

Ascendis Pharma AS Competitors

  • Who Are Ascendis Pharma AS's Competitors?
    Below is a list of companies who compete with Ascendis Pharma AS or are related in some way:
    • Akari Therapeutics PLC (AKTX)
    • Biodexa Pharmaceuticals PLC (BDRX)
    • Evaxion Biotech AS (EVAX)
    • Novo Nordisk AS (NVO)
    • TC BioPharm (Holdings) PLC (TCBP)

Ascendis Pharma AS Dividend Yield

Ascendis Pharma AS Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -14.45%
Revenue: 21.62% -16.51%

Analyst Recommendations

Buy Recommendations: 11
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 191.61
Upside from Last Price: 46.43%

Major Shareholders

  • How many ASND shares are owned by institutional investors?
    114.5M ASND shares are owned by institutional investors
  • How many ASND shares are owned by insiders?
    0 ASND shares are owned by insiders